294.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt UTHR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$274.70
Offen:
$284.65
24-Stunden-Volumen:
2.43M
Relative Volume:
4.25
Marktkapitalisierung:
$13.27B
Einnahmen:
$2.99B
Nettoeinkommen (Verlust:
$1.21B
KGV:
11.74
EPS:
25.06
Netto-Cashflow:
$1.13B
1W Leistung:
-3.36%
1M Leistung:
+1.16%
6M Leistung:
-16.20%
1J Leistung:
-10.22%
United Therapeutics Corp Stock (UTHR) Company Profile
Firmenname
United Therapeutics Corp
Sektor
Telefon
(301) 608-9292
Adresse
1000 SPRING ST, SILVER SPRING, MD
Vergleichen Sie UTHR mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
UTHR
United Therapeutics Corp
|
294.28 | 12.42B | 2.99B | 1.21B | 1.13B | 25.06 |
![]()
ZTS
Zoetis Inc
|
147.38 | 64.91B | 9.29B | 2.52B | 2.28B | 5.57 |
![]()
TAK
Takeda Pharmaceutical Co Adr
|
14.16 | 43.33B | 29.98B | 958.27M | 5.31B | 0.2964 |
![]()
HLN
Haleon Plc Adr
|
9.66 | 42.36B | 14.35B | 1.85B | 0 | 0.4023 |
![]()
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.38 | 17.72B | 16.54B | -1.64B | 749.00M | -1.45 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
2025-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2025-04-21 | Hochstufung | BofA Securities | Underperform → Neutral |
2024-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
2024-02-12 | Hochstufung | Goldman | Sell → Neutral |
2024-02-05 | Eingeleitet | Leerink Partners | Outperform |
2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
2022-12-06 | Eingeleitet | UBS | Buy |
2022-12-05 | Eingeleitet | Goldman | Sell |
2022-10-11 | Eingeleitet | Morgan Stanley | Overweight |
2022-09-20 | Bestätigt | BofA Securities | Underperform |
2022-09-19 | Fortgesetzt | Wedbush | Outperform |
2022-02-11 | Eingeleitet | BTIG Research | Neutral |
2021-07-14 | Hochstufung | Argus | Hold → Buy |
2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
2021-02-01 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
2020-06-25 | Bestätigt | H.C. Wainwright | Neutral |
2020-03-10 | Hochstufung | Jefferies | Hold → Buy |
2020-02-27 | Hochstufung | Cowen | Market Perform → Outperform |
2020-01-31 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-12-03 | Eingeleitet | BofA/Merrill | Underperform |
2019-08-01 | Hochstufung | Jefferies | Underperform → Hold |
2019-08-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
2019-07-01 | Hochstufung | Credit Suisse | Neutral → Outperform |
2019-05-17 | Hochstufung | UBS | Sell → Neutral |
2019-05-09 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-10-12 | Hochstufung | Standpoint Research | Hold → Buy |
2018-08-08 | Herabstufung | Credit Suisse | Neutral → Underperform |
2018-04-03 | Hochstufung | Credit Suisse | Underperform → Neutral |
2018-02-22 | Bestätigt | Barclays | Underweight |
2018-01-18 | Fortgesetzt | Credit Suisse | Underperform |
2017-12-27 | Bestätigt | Wedbush | Outperform |
2017-04-27 | Bestätigt | Wedbush | Outperform |
2017-03-30 | Eingeleitet | UBS | Sell |
2017-03-16 | Eingeleitet | Credit Suisse | Underperform |
Alle ansehen
United Therapeutics Corp Aktie (UTHR) Neueste Nachrichten
United Therapeutics Announces $1B Accelerated Share Repurchase Program. - AInvest
United Therapeutics’ PAH Study Update: Implications for Investors - TipRanks
United Therapeutics Advances in Pulmonary Fibrosis Treatment with Phase 3 Study - TipRanks
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics (UTHR) Launches $1B Stock Buyback Program - GuruFocus
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Call Transcript - Insider Monkey
United Therapeutics Launches $1 Bln Stock Buyback - Nasdaq
United Therapeutics stock jumps on $1 billion share repurchase plan - Investing.com
United Therapeutics Unveils Massive $1B Stock Buyback Plan in Strategic Financial Move - Stock Titan
Pulmonary Arterial Hypertension Drug Market to See Booming - openPR.com
What is the dividend policy of United Therapeutics Corporation stockFree Stock Alerts For Every Investor - jammulinksnews.com
United Therapeutics Reports Record Q2 2025 Financial Results - The Globe and Mail
BTIG Lowers Liquidia (LQDA) PT to $40, Potential for Yutrepia Launch Remains a Focus - Insider Monkey
United Therapeutics Reports Record Revenue and Growth - TipRanks
H.C. Wainwright lowers United Therapeutics stock price target on Tyvaso competition concerns - Investing.com Nigeria
United Therapeutics Corp (UTHR) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
United Therapeutics: Q2 Earnings Snapshot - Greenwich Time
Decoding United Therapeutics Corp (UTHR): A Strategic SWOT Insight - GuruFocus
United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment - TipRanks
United Therapeutics Stock Slides On Q2 Earnings: The Details - 富途牛牛
Earnings call transcript: United Therapeutics Q2 2025 misses EPS, stock drops - Investing.com
United Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary Fibrosis - TipRanks
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key Metrics - Nasdaq
United Therapeutics Q2 2025 slides: Revenue up 12% as Tyvaso drives growth - Investing.com India
United Therapeutics Logs Growth And Launches Big Buyback - Finimize
United Therapeutics misses Q2 earnings expectations By Investing.com - Investing.com Canada
United Therapeutics misses Q2 earnings expectations - Investing.com
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results - TradingView
UNITED THERAPEUTICS Corp SEC 10-Q Report - TradingView
United Therapeutics earnings missed by $0.94, revenue fell short of estimates - Investing.com
United Therapeutics Delivers Triple Win: Record $799M Revenue, $1B Buyback, and Major Pipeline Progress - Stock Titan
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial - MSN
United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer? - The Globe and Mail
Preview: United Therapeutics's Earnings - 富途牛牛
Bleecker Street Research short United Therapeutics, long Liquidia - TipRanks
Published on: 2025-07-29 12:41:34 - metal.it
United Therapeutics Earnings Announcement and Market OutlookNews and Statistics - IndexBox
Is There Enough Volume to Lift United Therapeutics CorporationTriple Return Setup With Risk Control Explained - metal.it
UBS Trims Price Target but Stays Bullish on United Therapeutics (UTHR) - MSN
Why United Therapeutics Corporation stock attracts strong analyst attentionWeekly Top Gainers Forecast Watchlist Released - metal.it
What institutions are buying United Therapeutics Corporation stock nowEarnings Play Trade Plan With Alerts Shared - metal.it
What To Expect From United Therapeutics’s (UTHR) Q2 Earnings - Yahoo.co
ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
How many analysts rate United Therapeutics Corporation as a “Buy”Entry Signal Forecasts With Low Risk - jammulinksnews.com
United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for Pulmonary Fibrosis - TipRanks
How volatile is United Therapeutics Corporation stock compared to the marketStay informed with daily expert analysis - jammulinksnews.com
What are the technical indicators suggesting about United Therapeutics CorporationRapid-fire capital growth - jammulinksnews.com
Leerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT - Insider Monkey
When is United Therapeutics Corporation stock expected to show significant growthHigh-performance stocks for savvy investors - jammulinksnews.com
Is United Therapeutics Corporation stock overvalued or undervaluedHigh-yield portfolio picks - jammulinksnews.com
Finanzdaten der United Therapeutics Corp-Aktie (UTHR)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):